Abstract
Individuals with autism spectrum disorder present with difficulties in social communication, restricted interests or behaviors and other co-morbidities. About 2 to 10% of cases of autism have a genetic cause, and Fragile X Syndrome (FXS) is reported in 0 to 6.5% of individuals with autism. However, the FXS and premutation prevalence among Filipino children has never been reported. The aim of the study was to establish the presence of FXS or premutation carriers among Filipino children with autism and to describe the phenotypic characteristic of cases identified. Blood was collected from 235 children aged 2–6 years old and diagnosed with autism. Samples were analyzed using PCR methods to amplify CGG repeats in the FMRI gene. The diagnosis of autism was confirmed through the Autism Diagnostic Observation Schedule-2. Additional characteristics were documented from a physical examination, Griffiths Scales of Child Development assessment and a parent-answered questionnaire using the Vineland Adaptive Behavior Scale. Fragile X testing through PCR methods in 235 children with diagnosed autism showed 220 (93.6%) were negative, no full mutations, 1 (0.436%) premutation carrier and 14 (5.95%) cases contained intermediate alleles. The FXS testing was limited to confirmed cases of autism, which is considered a high-risk group and does not provide prevalence for the general Filipino population. Subjects were self-referred or referred by clinicians, which may not represent the Filipino autism population with a bias towards those with means for clinical consultations and ability to travel to the place of testing. Samples were not measured for mosaicism, DNA methylation or AGG interspersion patterns. These may have effects on the CGG repeat expansion and overall presentation of FXS. Findings from a single premutation carrier cannot characterize features distinctly present in Filipinos with the mutation. Nevertheless, these results support the data that the prevalence of FXS in Asian populations may be lower than non-Asian populations. This can contribute to a better understanding of FXS and genetic causes of autism in the Philippines and other Asian populations.
Similar content being viewed by others
Abbreviations
- ADOS-2:
-
Autism Diagnostic Observation Schedule
- ASD:
-
Autism spectrum disorder
- FMR1:
-
Fragile X messenger ribonucleoprotein 1
- FMRP:
-
FMR1 protein
- FXAND:
-
Fragile X neuropsychiatric disorders
- FXS:
-
Fragile X Syndrome
- FXPOI:
-
Fragile X-associated Premature Ovarian Insufficiency
- FXTAS:
-
Fragile X-associated tremor/ataxia syndrome
- PCR:
-
Polymerase chain reaction
References
Abbeduto, L., Thurman, A. J., McDuffie, A., Klusek, J., Feigles, R. T., Ted Brown, W., et al. (2019). ASD comorbidity in fragile X syndrome: Symptom profile and predictors of symptom severity in adolescent and young adult males. Journal of Autism and Developmental Disorders, 49(3), 960–977.
Aishworiya, R., Protic, D., & Hagerman, R. (2022). Autism spectrum disorder in the fragile X premutation state: Possible mechanisms and implications. Journal of Neurology. https://doi.org/10.1007/s00415-022-11209-5
Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012). Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics. The Journal of Clinical Investigation, 122(12), 4314–4322.
Bailey, D. B., Raspa, M., Olmsted, M., & Holiday, D. B. (2008). Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. American Journal of Medical Genetics. Part A, 146A(16), 2060–2069.
Balicza, P., Varga, N. Á., Bolgár, B., Pentelényi, K., Bencsik, R., Gál, A., et al. (2019). Comprehensive analysis of rare variants of 101 autism-linked genes in a Hungarian cohort of autism spectrum disorder patients. Frontiers in Genetics, 8(10), 434.
Belmonte, M. K., & Bourgeron, T. (2006). Fragile X syndrome and autism at the intersection of genetic and neural networks. Nature Neuroscience, 9(10), 1221–1225.
Cai, X., Arif, M., Wan, H., Kornreich, R., & Edelmann, L. J. (2019). Clinical genetic testing for fragile X syndrome by polymerase chain reaction amplification and southern blot analyses. Methods in Molecular Biology Clifton NJ., 1942, 11–27.
Caravella, K. E., & Roberts, J. E. (2017). Adaptive skill trajectories in infants with fragile X syndrome contrasted to typical controls and infants at high risk for autism. Research in Autism Spectrum Disorder, 40, 1–12.
Chen, L., Hadd, A., Sah, S., Houghton, J. F., Filipovic-Sadic, S., Zhang, W., et al. (2011). High-resolution methylation polymerase chain reaction for fragile X analysis: Evidence for novel FMR1 methylation patterns undetected in Southern blot analyses. Genetics in Medicine, 13(6), 528–538.
Chen, T. A., Lu, X. F., Che, P. K., & Ho, W. K. (1997). Variation of the CGG repeat in FMR-1 gene in normal and fragile X Chinese subjects. Annals of Clinical Biochemistry, 34(Pt 5), 517–520.
Cheng, Y. K., Lin, C. S., Kwok, Y. K., Chan, Y. M., Lau, T. K., Leung, T. Y., et al. (2017). Identification of fragile X pre-mutation carriers in the Chinese obstetric population using a robust FMR1 polymerase chain reaction assay: Implications for screening and prenatal diagnosis. Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi, 23(2), 110–116.
Chonchaiya, W., Au, J., Schneider, A., Hessl, D., Harris, S. W., Laird, M., et al. (2012). Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Human Genetics, 131(4), 581–589.
Coffee, B., Keith, K., Albizua, I., Malone, T., Mowrey, J., Sherman, S. L., et al. (2009). Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. American Journal of Human Genetics, 85(4), 503–514.
Collins, S. C., Bray, S. M., Suhl, J. A., Cutler, D. J., Coffee, B., Zwick, M. E., et al. (2010). Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males. American Journal of Medical Genetics. Part A, 152A(10), 2512–2520.
Ergaz, Z., Weinstein-Fudim, L., & Ornoy, A. (2016). Genetic and non-genetic animal models for autism spectrum disorders (ASD). Reproductive Toxicology, 1(64), 116–140.
Estigarribia, B., Erwick Roberts, J., Sideris, J., & Price, J. (2010). Expressive morphosyntax in boys with Fragile X syndrome with and without autism spectrum disorder. International Journal of Language & Communication Disorders, 23, 1–15.
Farzin, F., Perry, H., Hessl, D., Loesch, D., Cohen, J., Bacalman, S., et al. (2006). Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. Journal of Developmental & Behavioral Pediatrics JDBP, 27(2 Suppl), S137-144.
Fernandez-Carvajal, I., Walichiewicz, P., Xiaosen, X., Pan, R., Hagerman, P. J., & Tassone, F. (2009). Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. The Journal of Molecular Diagnostics, 11(4), 324–329.
Filipovic-Sadic, S., Sah, S., Chen, L., Krosting, J., Sekinger, E., Zhang, W., et al. (2010). A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clinical Chemistry, 56(3), 399–408.
FRAXA Resaerch Foundation. (2022). FMR1 Renamed to Fragile X Messenger Ribonucleoprotein 1. Fragile X Research - FRAXA Research Foundation. Retrieved 6 May, 2022, from https://www.fraxa.org/fmr1-renamed-to-fragile-x-messenger-ribonucleoprotein-1/
Genereux, D. P., & Laird, C. D. (2013). Why do fragile X carrier frequencies differ between Asian and non-Asian populations? Genes & Genetic Systems, 88(3), 211–224.
Genetics Home Reference. (2018). FMR1 gene: MedlinePlus genetics. https://medlineplus.gov/genetics/gene/fmr1/
Geschwind, D. H. (2008). Autism: Many genes, common pathways? Cell, 135(3), 391–395.
Hadi, P., Haghani, K., Noori-Zadeh, A., & Bakhtiyari, S. (2018). Prevalence of fragile X syndrome among patients with mental retardation in the west of Iran. Frontiers of Biology, 13(6), 464–468.
Hagerman, R. J., & Hendren, R. L. (Eds.). (2014). Treatment of neurodevelopmental disorders: Targeting neurobiological mechanisms. Oxford University Press.
Hagerman, R. J., Protic, D., Rajaratnam, A., Salcedo-Arellano, M. J., Aydin, E. Y., & Schneider, A. (2018). Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatry., 9, 564.
Hnoonual, A., Jankittunpaiboon, C., & Limprasert, P. (2021). Screening for FMR1 CGG repeat expansion in Thai patients with autism spectrum disorder. BioMed Research International, 8(2021), e4359308.
Hoffmann, A., Thurman, A. J., Sterling, A., Kover, S. T., Finestack, L., Berry-Kravis, E., et al. (2022). Analysis of a repetitive language coding system: Comparisons between fragile X syndrome, autism, and down syndrome. Brain Sciences, 12(5), 575.
Hoyos, L. R., & Thakur, M. (2017). Fragile X premutation in women: Recognizing the health challenges beyond primary ovarian insufficiency. Journal of Assisted Reproduction and Genetics, 34(3), 315–323.
Hunter, J., Rivero-Arias, O., Angelov, A., Kim, E., Fotheringham, I., & Leal, J. (2014). Epidemiology of fragile X syndrome: A systematic review and meta-analysis. American Journal of Medical Genetics. Part A, 164A(7), 1648–1658.
Jiang, Y. H., Yuen, R. K., Jin, X., Wang, M., Chen, N., Wu, X., Ju, J., Mei, J., Shi, Y., He, M., & Wang, G. (2013). Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. The American Journal of Human Genetics, 93(2), 249–263.
Kim, M. J., Kim, D. J., Kim, S. Y., Yang, J. H., Kim, M. H., Lee, S. W., et al. (2013). Fragile X carrier screening in Korean women of reproductive age. Journal of Medical Screening, 20(1), 15–20.
Krishnan, A., Zhang, R., Yao, V., Theesfeld, C. L., Wong, A. K., Tadych, A., et al. (2016). Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder. Nature Neuroscience, 19(11), 1454–1462.
Lee, M., Martin, G. E., Berry-Kravis, E., & Losh, M. (2016). A developmental, longitudinal investigation of autism phenotypic profiles in fragile X syndrome. Journal of Neurodevelopmental Disorders, 8, 47.
Maenner, M. J., Baker, M. W., Broman, K. W., Tian, J., Barnes, J. K., Atkins, A., et al. (2013). FMR1 CGG expansions: Prevalence and sex ratios. American Journal of Medical Genetics Part B, 162B(5), 466–473.
Martin, G. E., Roberts, J. E., Helm-Estabrooks, N., Sideris, J., Vanderbilt, J., & Moskowitz, L. (2012). Perseveration in the connected speech of boys with Fragile X syndrome with and without autism spectrum disorder. American Journal on Intellectual and Developmental Disabilities, 117(5), 384–399.
Milà, M., Kruyer, H., Glover, G., Sánchez, A., Carbonell, P., Castellví-Bell, S., et al. (1994). Molecular analysis of the (CGG)n expansion in the FMR-1 gene in 59 Spanish fragile X syndrome families. Human Genetics, 94(4), 395–400.
Myrick, L. K., Nakamoto-Kinoshita, M., Lindor, N. M., Kirmani, S., Cheng, X., & Warren, S. T. (2014). Fragile X syndrome due to a missense mutation. European Journal of Human Genetics, 22(10), 1185–1189.
Nussbaum, R., McInnes, R., & Willard, H. (2016). Patterns of single gene inheritance. Thompson & Thompson genetics in medicine (8th ed.). Elsevier.
Otsuka, S., Sakamoto, Y., Siomi, H., Itakura, M., Yamamoto, K., Matumoto, H., et al. (2010). Fragile X carrier screening and FMR1 allele distribution in the Japanese population. Brain & Development, 32(2), 110–114.
Pembrey, M. E., Barnicoat, A. J., Carmichael, B., Bobrow, M., & Turner, G. (2001). An assessment of screening strategies for fragile X syndrome in the UK. Health Technology Assessment, 5(7), 1–95.
Reddy, K. S. (2005). Cytogenetic abnormalities and fragile-X syndrome in autism spectrum disorder. BMC Medical Genetics, 18(6), 3.
Saldarriaga-Gil, W., Cabal-Herrera, A. M., Fandiño-Losada, A., Vásquez, A., Hagerman, R., & Tassone, F. (2021). Inequities in diagnosis of Fragile X syndrome in Colombia. Journal of Applied Research in Intellectual Disabilities, 34(3), 830–839.
SFARI Gene - Welcome [Internet]. (2022). SFARI Gene. https://gene.sfari.org/
Shoaib, A., Cepeda, M. S., Murray, G., & Ochs-Ross, R. (2021). Autism: Comorbidities and treatment patterns in the real world, a retrospective cohort study among children, adolescents and adults newly diagnosed with autism. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-021-05289-x
Sihombing, N. R. B., Winarni, T. I., Utari, A., van Bokhoven, H., Hagerman, R. J., & Faradz, S. M. (2021). Surveillance and prevalence of fragile X syndrome in Indonesia. Intractable Rare Dis Res., 10(1), 11–16.
Snow, K., Doud, L., Hagerman, R., Pergolizzi, R., Erster, S., & Thibodeau, S. (1993). Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. American Journal of Human Genetics, 53(6), 1217–1228.
Tanchanco, L. (2014). Validity and reliability of filipino version of the modified checklist for autism toddlers (M-CHAT:FV). University of the Philippines.
Tassanakijpanich, N., Hagerman, R. J., & Worachotekamjorn, J. (2021). Fragile X premutation and associated health conditions: A review. Clinical Genetics, 99(6), 751–760.
Tassone, F. (2015). Advanced technologies for the molecular diagnosis of fragile X syndrome. Expert Review of Molecular Diagnostics, 15(11), 1465–1473.
Tassone, F., Iong, K. P., Tong, T. H., Lo, J., Gane, L. W., Berry-Kravis, E., et al. (2012). FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Medicine, 4(12), 100.
Tassone, F., & Milà, M. (2017). Chapter 3: Molecular diagnostics and genetic counseling in fragile X syndrome and FMR1-associated disorders. In R. Willemsen & R. F. Kooy (Eds.), Fragile X syndrome (pp. 41–55). Academic Press.
Tassone, F., Pan, R., Amiri, K., Taylor, A. K., & Hagerman, P. J. (2008). A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. The Journal of Molecular Diagnostics, 10(1), 43–49.
Thurman, A. J., McDuffie, A., Hagerman, R. J., Josol, C. K., & Abbeduto, L. (2017). Language skills of males with fragile X syndrome or nonsyndromic autism spectrum disorder. Journal of Autism and Developmental Disorders, 47(3), 728–743.
Turner, G., Robinson, H., Laing, S., Goddard, A., van den Berk, M., Sherman, S., et al. (1992). Population screening for fragile X. The Lancet, 339(8803), 1210–1213.
Wang, Y. C., Li, C., Lin, M. L., Lin, W. H., & Li, S. Y. (2000). Molecular diagnosis of fragile X syndrome and distribution of CGG repeats in the FMR-1 gene in Taiwanese. Journal of the Formosan Medical Association = Taiwan Yi Zhi, 99(5), 402–407.
Winarni, T. I., Utari, A., Mundhofir, F. E. P., Hagerman, R. J., & Faradz, S. M. H. (2013). Fragile X syndrome: Clinical, cytogenetic and molecular screening among autism spectrum disorder children in Indonesia. Clinical Genetics, 84(6), 577–580.
Wolff, J. J., Bodfish, J. W., Hazlett, H. C., Lightbody, A. A., Reiss, A. L., & Piven, J. (2012). Evidence of a distinct behavioral phenotype in young boys with fragile X syndrome and autism. Journal of the American Academy of Child and Adolescent Psychiatry, 51(12), 1324–1332.
Yang, Y., Tian, J., & Yang, B. (2018). Targeting gut microbiome: A novel and potential therapy for autism. Life Sciences, 194, 111–119.
Yoon, S. H., Choi, J., Lee, W. J., & Do, J. T. (2020). Genetic and epigenetic etiology underlying autism spectrum disorder. Journal of Clinical Medicine, 9(4), 966.
Yrigollen, C. M., Durbin-Johnson, B., Gane, L., Nelson, D. L., Hagerman, R., Hagerman, P. J., et al. (2012). AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genetics in Medicine, 14(8), 729–736.
Acknowledgments
We are grateful to the families who participated in the research project of the Ateneo Autism Study Group. We also acknowledge the contributions of the following individuals and organizations who provided support to be able to complete the study: CHED-PCARI, Ateneo Center for Research and Innovations, Dr. Eva Cutiongco-dela Paz and the Philippine Genome Center, Dr. Flora Tassone and her laboratory research team and the University of California Davis - MIND Institute, Dr. Feriza Isaguirre with Ms. Maria Catherine B. Otero and Dr. Genevieve Tupas of Davao Medical School Foundation, Inc. and Brokenshire Hospital, Dr. Celina Gellada of West Visayas State University, the Philippine Society for Developmental and Behavioral Pediatrics, past and present clinicians and research assistants of the Ateneo Autism Study Group.
Funding
Funding was provided by Philippine-California Advanced Research Institutes (Grant No. IHITM 2017-024).
Author information
Authors and Affiliations
Contributions
ABCD and LST are co-primary authors who both conducted the clinical assessments of the participants, contributed to the study design, interpreted the data, drafted and reviewed the manuscript. JCS performed the FXS genetic testing, drafted the manuscript, and interpreted the results. MDL performed the sample collection and reviewed the data and manuscript. RJH provided mentorship and contributed to the discussion in the manuscript. All the authors have read and approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Dy, A.B.C., Tanchanco, L.B.S., Sy, J.C.Y. et al. Screening for Fragile X Syndrome Among Filipino Children with Autism Spectrum Disorder. J Autism Dev Disord 53, 4465–4473 (2023). https://doi.org/10.1007/s10803-022-05707-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10803-022-05707-8